RUNX1 promotes MAPK signaling to increase tumor progression and metastasis via OPN in head and neck cancer. (11th November 2020)

• Record Type: Journal Article
• Authors: Liu, Kai; Hu, Huiying; Jiang, Huanyu; Zhang, Haidong; Gong, Shanchun; Wei, Dongmin; Yu, Zhenkun
• Is Part Of: Carcinogenesis. Volume 42:Number 3(2021)
• Page Start: 414
• Page End: 422
• Publication Date: 2020-11-11
• Subjects: Carcinogenesis -- Periodicals; Cancer -- Genetic aspects -- Periodicals; Cancer -- Prevention -- Periodicals; Cancer -- Periodicals; 616.994071
• DOI: 10.1093/carcin/bgaa116
• Languages: English
• ISSNs: 0143-3334

Abstract

Abstract: Tumor progression and metastasis are still major burdens for head and neck squamous cell carcinoma (HNSCC). Runt-related transcription factor 1 (RUNX1) is involved in aggressive phenotypes in several cancers, while the molecular role of RUNX1 underlying cancer progression and metastasis of HNSCC remains largely unknown. In our study, RUNX1 expression was increased with disease progression in patients with HNSCC. The silencing of RUNX1 significantly decelerated the malignant progression of HNSCC cells, reduced osteopontin (OPN) expression in vitro and weakened the tumorigenicity of HNSCC cells in vivo . Moreover, we demonstrated that RUNX1 activated the mitogen-activated protein kinase signaling by directly binding to the promoter of OPN in tumor progression and metastasis of HNSCC. Our results may provide new insight into the mechanisms underlying the role of RUNX1 in tumor progression and metastasis and reveal the potential therapeutic target in HNSCC. Abstract : RUNX1 expression was increased with disease progression, which activated the MAPK signaling by directly binding to the promoter of OPN in tumor progression and metastasis of HNSCC.